Latest News about BNTX
Recent news which mentions BNTX
From Benzinga
Why BioNTech Stock Dropped 12.4% in February
March 07, 2022
From Motley Fool
Benzinga Bulls And Bears Of The Past Week: Shopify, Palantir, Apple, Meta, Twitter, Johnson & Johnson, American Express And More
March 05, 2022
From Benzinga
From Motley Fool
From Motley Fool
Why Moderna and BioNTech Tumbled on Thursday
March 03, 2022
From Motley Fool
Johnson & Johnson's COVID-19 Vaccine Less Effective Against Hospitalization, French Study Shows
March 03, 2022
From Benzinga
From Motley Fool
Is BioNTech Stock a Buy Now?
March 02, 2022
From Motley Fool
Markets Fall As Russia-Ukraine Tensions Escalate; American Express, Boeing See Sharp Drops
March 01, 2022
From Benzinga
Pfizer/BioNTech's COVID-19 Vaccine Mere 12% Effective In Kids 5-11 Years, New York Study Shows
March 01, 2022
From Benzinga
From MarketWatch
Maravai LifeSciences Rejects Sartorius' $11B Takeover Bid: Reuters
February 28, 2022
From Benzinga
From Motley Fool
Moderna’s Covid Shot Alone Isn’t Enough to Revitalize a Sagging Stock
February 25, 2022
From InvestorPlace
Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests
February 25, 2022
From Benzinga
Got $5,000? These 2 Growth Stocks Are Down 60% From Their Highs
February 24, 2022
From Motley Fool
Why Novavax Stock Dived by Over 7% Today
February 23, 2022
From Motley Fool
From Benzinga
BioNTech, Medigene Ink Immunotherapy Pact Against Cancer
February 22, 2022
Tickers
BNTX
From Benzinga
Why Novavax Has Limited Downside from Here
February 21, 2022
From InvestorPlace
Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline
February 18, 2022
From Benzinga
If You Invested $10,000 in BioNTech 2 Years Ago, This Is How Much You Would Have Today
February 18, 2022
From Motley Fool
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 17, 2022
From Benzinga
U.S. headed closer to point where pandemic is no longer a crisis, White House says, but sticks with face masks for now
February 17, 2022
From MarketWatch
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart
February 17, 2022
From Benzinga
2 Reasons Why Pfizer Might Crush Moderna in the mRNA Market. And 1 Reason Why Moderna May Stay Ahead.
February 17, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.